Media

On the afternoon of August 26, the “Dongguan Biotech Enterprises Going Global to Singapore Consultation and Exchange Forum” was successfully held in Songshan Lake, Dongguan. The event was hosted by Dongguan Biotechnology Industry Development Co., Ltd., co-organized by SIG global and the Dongguan Biotechnology Industry Association, and supported by the Administrative Committee of Dongguan Songshan Lake High-Tech Industrial Development Zone.

This closed-door exchange focused on policy opportunities, financing pathways, and landing services for biopharmaceutical enterprises expanding into Singapore, attracting nearly 30 representatives from government, enterprises, capital, and research institutions.

At the event, Xie Weijian, Director of the South China Office of the Singapore Economic Development Board (EDB), delivered a keynote speech, providing a comprehensive overview of Singapore’s policy advantages and ecosystem in the biopharmaceutical industry.

Liu Hongpeng, Director of the Asia-Pacific Business Division at SIG Global, shared practical insights with participating enterprises, interpreting the latest opportunities and implementation pathways for entering the Southeast Asian market.

Li Rui, Partner at Button Capital, provided Dongguan enterprises with perspectives, strategies, and case studies on “going global with innovative drugs” from a capital standpoint.

The exchange also marked an important milestone: Dongguan Biotechnology Industry Development Co., Ltd. and SIG Global officially signed a strategic cooperation agreement.

This signing not only represents a deep partnership between the two companies but also signifies the establishment of a direct bridge connecting Dongguan biotech enterprises with Singapore and Southeast Asian markets. It creates a practical, two-way platform that empowers Dongguan enterprises to expand overseas while facilitating the integration of Singaporean resources into Dongguan.

SIG Global will take this collaboration as a starting point to continuously build a resource bridge between China and Singapore for Dongguan biotech enterprises, facilitating efficient connections with Singapore’s government and financial resources. It will provide end-to-end services covering compliance, taxation, and market entry support, helping enterprises accelerate their pace of internationalization.

With its globalized research environment, policy advantages, and financial channels, Singapore has become a key springboard for Chinese biopharmaceutical companies to expand abroad. Meanwhile, Songshan Lake in Dongguan, as a hub of scientific and technological innovation in the Greater Bay Area, is actively connecting with international resources to create platforms that support local enterprises in going global.

This exchange not only gave Dongguan enterprises a clearer understanding of Singapore’s biopharmaceutical industry ecosystem but also injected fresh momentum into China–Singapore collaboration. Looking ahead, SIG Global will continue to build efficient pathways for international expansion, helping more local biotech enterprises step onto the global stage.